Autobahn Therapeutics

The first half of July brought an explosion of venture capital fireworks with several $100m-plus financings for biopharmaceutical companies, but the pace of mega-round announcements has fizzled out in

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Boehringer Ingelheim Acquires Nerio The

Autobahn Therapeutics wanted to take advantage of the neuropsychiatric benefits observed with thyroid hormone therapy without systemic side effects, so the company used its proprietary technology for

A bevy of big venture capital financings have been announced since Labor Day, the official end of summer in the US, led by a $300m series C round for Acelyrin, Inc. The boom in VC mega-deals is rema